Zymogenetics, Inc.

Regeneron Pharmaceuticals, Inc.

Stephen R Jaspers

Scott R Presnell

Monica J Huber

Paul O Sheppard

Darrell C Conklin

Steven D Levin

Si Lok

Paul D Bishop

Theresa A Deisher

Katherine E Lewis

Zeren Gao

Mark W Rixon

Stacey R Dillon

Pallavur V Sivakumar

Eugene C Yi

Cecile Krejsa

Catherine E Lofton-Day

Robert Mabry

Frederick J Ramsdell

Yasmin A Chandrasekher

Virender M Labroo

Donald C Foster

Julia E Novak

Janine M Bilsborough

Wenfeng Xu

Jesper Gromada

Haruka Okamoto

Rolf E Kuestner

Joyce Harp

Robyn L Adams

Anna C Jelmberg

Michael R Stamm

Jacqueline M Humes

George Robert Mabry, Iii

Hong Ping Ren

Katherine H Sprugel

Gayle Yamamoto

Cecile M Krejsa

Cindy A Sprecher

James D Kelly

Penny Thompson

Hal Blumberg

Steven K Burkhead

Karen L Madden

Sherri L Mudri

Ross C Hoffman

Maribeth A Eagan

Monica Huber

Xu Wenfeng

Maribeth A Eagen

Provided herein are methods of treating a patient with severe insulin resistance. The methods comprise administering to a patient in need thereof a therapeutic amount of a GCG/GCGR signaling pathway inhibitor, such that blood glucose or beta-hydroxybutyrate levels are lowered or that the severe insulin resistance is mediated, or a condition or disease characterized by severe insulin resistance is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity. The GCG/GCGR signaling pathway inhibitor can be a small molecule inhibitor of the signaling pathway, an antisense inhibitor of the signaling pathway, a GCG neutralizing monoclonal antibody, a GCGR antagonist, a peptide inhibitor of the signaling pathway, a DARPin, a Spiegelmer, an aptamer, engineered Fn type-III domains, etc. The therapeutic methods are useful for treating a human suffering from severe insulin resistance.

Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.

Use of IL-17A and IL-17F cross-reactive monoclonal antibodies for treating inflammatory diseases

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Treating inflammation with IL-17/IL-23 bispecific antibodies

Methods of treating inflammation using IL-17A and IL-17F cross-reactive monoclonal antibodies

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.

Monoclonal antibodies that bind both IL-17A and IL-17F

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.

Use of an IL-17/IL-23 bispecific antibody for treating inflammation

Antibodies that bind both IL-17A and IL-17F

Polynucleotides encoding antagonists of IL-17A, IL-17F, and IL-23p19

The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.

Methods of treating inflammatory diseases using antibodies that bind both IL-17A and IL-17F

Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

Anti-human IL-21 antibodies

Antagonists of IL-17A, IL-17F, and IL-23P19

Polynucleotides encoding antibodies that bind both IL-17A and IL-17F

Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R&#x3b3;; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.

Methods for treating disease using an anti-IL-21 receptor antibody

Growing community of inventors

Edmonds, WA, United States of America

Stephen R Jaspers